<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104739</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-13-0791</org_study_id>
    <nct_id>NCT02104739</nct_id>
  </id_info>
  <brief_title>Effects of Antidiabetic Medications on the Postprandial State in Prediabetes</brief_title>
  <official_title>Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project addresses cardiovascular disease risk in patients with prediabetes. Levels of
      lipids after eating a meal (&quot;postprandial lipids&quot;) are strong independent predictors of
      cardiovascular risk. Newer anti-diabetic agents - exenatide and saxagliptin - impact lipid
      metabolism. These medications will be studied for their effect in reducing both postprandial
      lipid levels and arterial dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a paradox that medical efforts to control blood glucose in type 2 diabetes mellitus
      have not decreased the risk of cardiovascular disease. Postprandial lipid concentrations are
      a strong predictor of cardiovascular risk, independent of traditional cardiovascular risk
      factors. The new classes of antidiabetic medications - GLP-1 agonists and DPP-IV inhibitors -
      affect lipid as well as glucose metabolism. This study will investigate the efficacy of these
      medications in reducing postprandial hyperlipidemia, disrupting the concurrent
      proinflammatory free fatty acid signaling, and ameliorating endothelial dysfunction in
      individuals with prediabetes. This will consist of a single center, randomized, crossover,
      placebo-controlled double-blinded prospective trial involving three study arms representing
      the aforementioned medications: exenatide (GLP-1 agonist), saxagliptin (DPP-IV inhibitor),
      and placebo (control arm). Each subject will participate in each of the three arms, which are
      three separate, daylong outpatient studies. For each study arm, subjects will eat a
      standardized atherogenic high-fat test lunch. Venous blood draws and measurements of forearm
      blood flow will be done prior to the meal and periodically during a 6-hour period after the
      meal. Forearm blood flow measurements will assess for changes in endothelial function. The
      blood will be analyzed for multiple markers of hyperlipidemia and free fatty acid signaling.
      After completing the three randomized study visits, subjects are invited to participate in an
      optional, nonrandomized extension study. For the extension study, subjects will take
      exenatide ER (extended-release exenatide) weekly for total of six weeks. Then subjects return
      to eat a standardized atherogenic high-fat test lunch. Venous blood draws and measurements of
      forearm blood flow will be done prior to the meal and periodically during a 4-hour period
      after the meal, for the same analyses described before. The results will provide new insights
      into the anti-inflammatory effects of multiple antidiabetic medications via the mechanisms of
      postprandial hyperlipidemia, free fatty acid signaling, and endothelial function in
      prediabetic individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo pills and placebo injections provided</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte NfkB Levels as Detected by Western Blotting</measure>
    <time_frame>baseline</time_frame>
    <description>Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocyte NfkB Levels as Detected by Western Blotting</measure>
    <time_frame>2 hours after ingestion of meal</time_frame>
    <description>Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>baseline</time_frame>
    <description>triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>2 hours after ingestion of meal</time_frame>
    <description>triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>4 hours after ingestion of meal</time_frame>
    <description>triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>6 hours after ingestion of meal</time_frame>
    <description>triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acids</measure>
    <time_frame>baseline</time_frame>
    <description>Free Fatty Acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acids</measure>
    <time_frame>2 hours after meal</time_frame>
    <description>Free Fatty Acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acids</measure>
    <time_frame>4 hours after meal</time_frame>
    <description>Free Fatty Acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acids</measure>
    <time_frame>6 hours after meal</time_frame>
    <description>Free Fatty Acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forearm Blood Flow</measure>
    <time_frame>baseline</time_frame>
    <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forearm Blood Flow</measure>
    <time_frame>3 hours after meal</time_frame>
    <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forearm Blood Flow</measure>
    <time_frame>6 hours after meal</time_frame>
    <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Prediabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide, then Exenatide ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide, then Exenatide ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Single subcutaneous injection (10 mcg)</description>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin</arm_group_label>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide, then Exenatide ER</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Single dose orally (5 mg)</description>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin</arm_group_label>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide, then Exenatide ER</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide extended-release (ER)</intervention_name>
    <description>Subcutaneous injection (2mg) weekly for 6 weeks</description>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide, then Exenatide ER</arm_group_label>
    <other_name>Bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets and Placebo (normal saline) injections</description>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin</arm_group_label>
    <arm_group_label>Exenatide, then Placebo, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo</arm_group_label>
    <arm_group_label>Exenatide, then Saxagliptin, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin</arm_group_label>
    <arm_group_label>Placebo, then Exenatide, then Saxagliptin, then Exenatide ER</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide</arm_group_label>
    <arm_group_label>Placebo, then Saxagliptin, then Exenatide, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo</arm_group_label>
    <arm_group_label>Saxagliptin, then Exenatide, then Placebo, then Exenatide ER</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide</arm_group_label>
    <arm_group_label>Saxagliptin, then Placebo, then Exenatide, then Exenatide ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting glucose
             of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood glucose of
             140-199 mg/dL after 75 gram oral glucose challenge), and/or a hemoglobin A1C ranging
             from 5.7% to 6.4%

          -  Subjects are allowed, but not required, to be on statins, ACE-inhibitors,
             beta-blockers, angiotensin-receptor blockers, thiazide diuretics, and/or loop
             diuretics at doses that have been stable for at least the last 3 months

          -  BMI between 30-35 kg/m2 (±1 kg/m2)

          -  Body weight has been stable (±4-5 pounds) over the prior three months.

          -  Women of childbearing age must agree to use an acceptable method of pregnancy
             prevention (barrier methods, abstinence, or surgical sterilization) for the duration
             of the study

          -  Patients must have the following laboratory values: Hematocrit ≥ 34 vol% S. creatinine
             &lt; 1.5 mg/dl in men and 1.4 mg/dl in women AST (SGOT) &lt; 2.5 times ULN, ALT (SGPT) &lt; 2.5
             times ULN, alkaline phosphatase&lt; 2.5 times ULN

        Exclusion Criteria:

          -  History of Type 1 or Type 2 diabetes mellitus

          -  History of diabetic ketoacidosis or hyperosmolar nonketotic coma

          -  Pregnant or breastfeeding women

          -  Patients must not be receiving lipid-lowering medications other than statins within
             the last 3 months

          -  Patient must not be receiving metformin, DPP-IV inhibitors, GLP-1 agonists,
             thiazolidinediones, insulin, sulfonylureas, acarbose, SGLT-2 inhibitors,
             corticosteroids, or immunosuppressive therapy within the last 3 months and cannot take
             them for the duration of the study. Patient must not be receiving NSAIDS or
             antioxidant vitamins within the last 1 week, and cannot take them for the duration of
             the study.

          -  Patients must not be on hormone replacement therapy.

          -  Patients with diabetic gastroparesis

          -  Patients with current tobacco use

          -  Patients with active malignancy

          -  Patients with history of urinary bladder cancer

          -  Patients with dietary restrictions precluding a high-fat meal

          -  Patients with a history of clinically significant heart disease (NYHA III or IV; more
             than non- specific ST-T wave changes on the EKG), peripheral vascular disease (history
             of claudication), or pulmonary disease (dyspnea on exertion of one flight or less;
             abnormal breath sounds on auscultation) will not be studied

          -  Subjects with a history of any serious hypersensitivity reaction to the study
             medications

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (e.g., infectious disease) illness

          -  Subjects with known allergic reactions to the study medications or test meal

          -  Subjects unwilling or unable to provide informed consent

          -  Subjects determined by the investigator(s) to not be appropriate candidates for the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Absalaon D Gutierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center at Houston, Dept. of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <results_first_submitted>March 20, 2018</results_first_submitted>
  <results_first_submitted_qc>June 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2018</results_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Absalon D Gutierrez</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>prediabetes</keyword>
  <keyword>diabetes mellitus type 2</keyword>
  <keyword>exenatide</keyword>
  <keyword>saxagliptin</keyword>
  <keyword>exenatide ER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02104739/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>21 subjects were enrolled. 20 were randomized, and these 20 participated in each of three arms (the exenatide, saxagliptin, and placebo arms), with the order of receipt being randomized. There was an extension phase (that is, the exenatide extended-release (ER) arm) in which 8 of the 21 enrolled participated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide, Then Saxagliptin, Then Placebo</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Exenatide, Then Placebo, Then Saxagliptin</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Saxagliptin, Then Exenatide, Then Placebo</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
        <group group_id="P4">
          <title>Saxagliptin, Then Placebo, Then Exenatide</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
        <group group_id="P5">
          <title>Placebo, Then Exenatide, Then Saxagliptin</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Then Saxagliptin, Then Exenatide</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
        <group group_id="P7">
          <title>Exenatide Extended-release (Extension Phase)</title>
          <description>Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (Min of 10 and Max of 107 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (Min of 10 and Max of 107 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (Min of 10 and Max of 323 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Phase (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>This was a crossover study in which the 21 who were enrolled participated in each of three arms (the exenatide, saxagliptin, and placebo arms). There was an extension phase (that is, the exenatide extended-release (ER) arm) in which 8 of the 21 enrolled participated.
Exenatide arm: Single subcutaneous injection (10 mcg) Saxagliptin arm: Single dose orally (5 mg) Placebo arm: Placebo tablets and Placebo (normal saline) injections Exenatide extended-release (ER) arm: Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Height is reported for those who participated in the three main arms of the study (exenatide, saxagliptin, and placebo arms) but not separately reported for the extension study (extended-release exenatide). All those who participated in the extension study also participated in the three main arms of the study.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Weight is reported for those who participated in the three main arms of the study (exenatide, saxagliptin, and placebo arms) but not separately reported for the extension study (extended-release exenatide). All those who participated in the extension study also participated in the three main arms of the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.96" spread="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>BMI is reported for those who participated in the three main arms of the study (exenatide, saxagliptin, and placebo arms) but not separately reported for the extension study (extended-release exenatide). All those who participated in the extension study also participated in the three main arms of the study.</population>
          <units>kilograms per meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.53" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Monocyte NfkB Levels as Detected by Western Blotting</title>
        <description>Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte NfkB Levels as Detected by Western Blotting</title>
          <description>Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.</description>
          <units>NfkB p65 arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.79" spread="4.05"/>
                    <measurement group_id="O2" value="72.03" spread="6.38"/>
                    <measurement group_id="O3" value="67.68" spread="6.38"/>
                    <measurement group_id="O4" value="84.19" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monocyte NfkB Levels as Detected by Western Blotting</title>
        <description>Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.</description>
        <time_frame>2 hours after ingestion of meal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte NfkB Levels as Detected by Western Blotting</title>
          <description>Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.</description>
          <units>NfkB p65 arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.39" spread="6.44"/>
                    <measurement group_id="O2" value="68.39" spread="5.82"/>
                    <measurement group_id="O3" value="71.37" spread="5.82"/>
                    <measurement group_id="O4" value="93.47" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Exenatide at baseline and 2 hours after ingestion of meal is compared.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Non-parametric Wilcoxon paired rank sum</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Saxagliptin at baseline and 2 hours after ingestion of meal is compared.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Non-parametric Wilcoxon paired rank sum</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Placebo at baseline and 2 hours after ingestion of meal is compared.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Non-parametric Wilcoxon paired rank sum</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Exenatide extended-release (ER) at baseline and 2 hours after ingestion of meal is compared.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Non-parametric Wilcoxon paired rank sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>triglycerides</description>
        <time_frame>baseline</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>triglycerides</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" spread="11"/>
                    <measurement group_id="O2" value="101" spread="11"/>
                    <measurement group_id="O3" value="102" spread="14"/>
                    <measurement group_id="O4" value="106" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>triglycerides</description>
        <time_frame>2 hours after ingestion of meal</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>triglycerides</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="13"/>
                    <measurement group_id="O2" value="130" spread="16"/>
                    <measurement group_id="O3" value="163" spread="19"/>
                    <measurement group_id="O4" value="168" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>triglycerides</description>
        <time_frame>4 hours after ingestion of meal</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>triglycerides</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="12"/>
                    <measurement group_id="O2" value="153" spread="24"/>
                    <measurement group_id="O3" value="206" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>triglycerides</description>
        <time_frame>6 hours after ingestion of meal</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>triglycerides</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" spread="24"/>
                    <measurement group_id="O2" value="179" spread="27"/>
                    <measurement group_id="O3" value="200" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The reported p-value compares exenatide and saxagliptin over all time points (2 hours, 4 hours, 6 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The reported p-value compares exenatide and placebo over all time points (2 hours, 4 hours, 6 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Fatty Acids</title>
        <description>Free Fatty Acids</description>
        <time_frame>baseline</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fatty Acids</title>
          <description>Free Fatty Acids</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.04"/>
                    <measurement group_id="O2" value="0.49" spread="0.05"/>
                    <measurement group_id="O3" value="0.51" spread="0.04"/>
                    <measurement group_id="O4" value="0.65" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Fatty Acids</title>
        <description>Free Fatty Acids</description>
        <time_frame>2 hours after meal</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fatty Acids</title>
          <description>Free Fatty Acids</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.05"/>
                    <measurement group_id="O2" value="0.18" spread="0.02"/>
                    <measurement group_id="O3" value="0.17" spread="0.01"/>
                    <measurement group_id="O4" value="0.19" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Fatty Acids</title>
        <description>Free Fatty Acids</description>
        <time_frame>4 hours after meal</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fatty Acids</title>
          <description>Free Fatty Acids</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.06"/>
                    <measurement group_id="O2" value="0.24" spread="0.02"/>
                    <measurement group_id="O3" value="0.23" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Fatty Acids</title>
        <description>Free Fatty Acids</description>
        <time_frame>6 hours after meal</time_frame>
        <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fatty Acids</title>
          <description>Free Fatty Acids</description>
          <population>Data for the exenatide extended-release (ER) arm was only collected at baseline and 2 hours.</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.06"/>
                    <measurement group_id="O2" value="0.31" spread="0.02"/>
                    <measurement group_id="O3" value="0.33" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The reported p-value compares exenatide and saxagliptin over all time points (2 hours, 4 hours, 6 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The reported p-value compares exenatide and placebo over all time points (2 hours, 4 hours, 6 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forearm Blood Flow</title>
        <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
        <time_frame>baseline</time_frame>
        <population>Though 16 completed the exenatide, saxagliptin, and placebo arms, data is only reported for 15 because the study team was unsuccessful in collecting data for the first study patient. Data for the exenatide extended-release (ER) arm was only collected at baseline and 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forearm Blood Flow</title>
          <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
          <population>Though 16 completed the exenatide, saxagliptin, and placebo arms, data is only reported for 15 because the study team was unsuccessful in collecting data for the first study patient. Data for the exenatide extended-release (ER) arm was only collected at baseline and 3 hours.</population>
          <units>mL per minute per 100mL of tissue</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.65" spread="1.17"/>
                    <measurement group_id="O2" value="12.79" spread="1.47"/>
                    <measurement group_id="O3" value="12.18" spread="1.17"/>
                    <measurement group_id="O4" value="16.18" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forearm Blood Flow</title>
        <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
        <time_frame>3 hours after meal</time_frame>
        <population>Though 16 completed the exenatide, saxagliptin, and placebo arms, data is only reported for 15 because the study team was unsuccessful in collecting data for the first study patient. Data for the exenatide extended-release (ER) arm was only collected at baseline and 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forearm Blood Flow</title>
          <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
          <population>Though 16 completed the exenatide, saxagliptin, and placebo arms, data is only reported for 15 because the study team was unsuccessful in collecting data for the first study patient. Data for the exenatide extended-release (ER) arm was only collected at baseline and 3 hours.</population>
          <units>mL per minute per 100mL of tissue</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.18" spread="1.21"/>
                    <measurement group_id="O2" value="13.25" spread="1.04"/>
                    <measurement group_id="O3" value="15.11" spread="1.29"/>
                    <measurement group_id="O4" value="16.54" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forearm Blood Flow</title>
        <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
        <time_frame>6 hours after meal</time_frame>
        <population>Though 16 completed the exenatide, saxagliptin, and placebo arms, data is only reported for 15 because the study team was unsuccessful in collecting data for the first study patient. Data for the exenatide extended-release (ER) arm was only collected at baseline and 3 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: Single dose orally (5 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
          </group>
          <group group_id="O4">
            <title>Exenatide Extended-release (ER)</title>
            <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forearm Blood Flow</title>
          <description>Peak forearm blood flow via strain gauge venous occlusion plethysmography</description>
          <population>Though 16 completed the exenatide, saxagliptin, and placebo arms, data is only reported for 15 because the study team was unsuccessful in collecting data for the first study patient. Data for the exenatide extended-release (ER) arm was only collected at baseline and 3 hours.</population>
          <units>mL per minute per 100mL of tissue</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" spread="1.09"/>
                    <measurement group_id="O2" value="15.87" spread="1.81"/>
                    <measurement group_id="O3" value="13.45" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The reported p-value compares exenatide and saxagliptin over all time points (3 hours, 6 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The reported p-value compares exenatide and placebo over all time points (3 hours, 6 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were followed during the study and for 30 days following the last dose. During the cross-over study, subjects were followed for a min of 53 days to a max of 150 days after taking the 1st dose [(3 days for 3, 1-day study arms) + (20 days to 117 days total for 2 washout periods) + 30 = 53 days]. (Washout was at least 20 days but could be 117 days since the cross-over study could span 120 days.) During the extension study, subjects were followed for 72 days after taking the 1st dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>Exenatide: Single subcutaneous injection (10 mcg)</description>
        </group>
        <group group_id="E2">
          <title>Saxagliptin</title>
          <description>Saxagliptin: Single dose orally (5 mg)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Placebo tablets and Placebo (normal saline) injections</description>
        </group>
        <group group_id="E4">
          <title>Exenatide Extended-release (ER)</title>
          <description>Exenatide extended-release (ER): Subcutaneous injection (2mg) weekly for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lower than expected sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Absalon D Gutierrez, MD</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 500-6641</phone>
      <email>Absalon.D.Gutierrez@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

